close
Add to watchlist
Cadence Pharmaceuticals Inc (CADX)
Cadence Pharmaceuticals, Inc., a biopharmaceutical company, focuses on in-licensing, developing, and commercializing proprietary product candidates principally for use in the hospital setting in the United States and Canada. It has two Phase III product candidates in development, which include Acetavance, a proprietary intravenous formulation of acetaminophen for the treatment of acute pain and fever; and Omigard, an omiganan pentahydrochloride aqueous gel for the prevention of catheter-related infections. The company holds in-license rights to market Acetavance in Europe under the Perfalgan name and to commercialize Omigard for the prevention and treatment of device-related, surgical wound-related, and burn-related infections in North America and Europe. Cadence Pharmaceuticals, Inc. was founded in 2004 and is headquartered in San Diego, California.
(login to add this stock to your watchlist or favorites)
Key Statistics
| Closing Price | 3.51 |
| Volume | 430442 |
| Volume Avg | 358316 |
| 52 Week High | 10.00 |
| 52 Week Low | 3.41 |
| PE | N/A |
| PE (group average) | N/A |
| EPS Year | -1.37 |
| EPS change Q/Q | -18.18% |
| EPS change Q/Q Yr ago | -39.29% |
| EPS change Q/Q next Q est | -105.26% |
| EPS change Y/Y | -17.65% |
| REV change Q/Q | -100% |
| REV change Q/Q Yr ago | -100% |
| EPS next Q est | -0.19 |
| EPS next Y est | -0.04 |
| Divident Annual | 0.00 |
| Dividend Yield | 0% |